ALPHA.PA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 11:35):

Stats
Today's Volume	172 459
Average Volume	130 229
Market Cap	63 674.00
EPS	€0 ( 2024-05-31 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0.00100 (2.51%)

Volume Correlation

Long: 0.12 (neutral)

Short: 0.79 (moderate)

Signal:(53.744) Neutral

Pharnext SA Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Pharnext SA Correlation - Currency/Commodity

0.00
( neutral )

-0.18
( neutral )

Pharnext SA Financials

Annual	2023
Revenue:	€10 000.00
Gross Profit:	€10 000.00 (100.00 %)
EPS:	€-200.00

FY	2023
Revenue:	€10 000.00
Gross Profit:	€10 000.00 (100.00 %)
EPS:	€-200.00

FY	2022
Revenue:	€558.00
Gross Profit:	€2.26M (404 643.19 %)
EPS:	€-8.32

FY	2021
Revenue:	€84 785.00
Gross Profit:	€0.00 (0.00 %)
EPS:	€-5 033.08

Financial Reports:

No articles found.

Pharnext SA Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Pharnext SA

Pharnext SA, a clinical-stage biopharmaceutical company, develops therapies for orphan and common neurodegenerative diseases in France. The company's products include SYNGILITY that has completed Phase III trial for the treatment of Charcot-Marie-Tooth disease type 1A; and PXT864, which has completed Phase II clinical trial to treat Alzheimer's disease, as well as Parkinson's disease and amyotrophic lateral sclerosis. It also develops PLEOTHERAPY, a big genetic data and artificial intelligence platform. Pharnext SA has an agreement with the University Hospital Institute Mediterranee Infection to evaluate repurposed drugs for potential use against the COVID-19 virus. The company was founded in 2007 and is headquartered in Issy-Les-Moulineaux, France.